Immunome, Inc.
Clinical trials sponsored by Immunome, Inc., explained in plain language.
-
New Antibody-Drug conjugate enters human trials for advanced cancers
Disease control Recruiting nowThis early-stage trial tests IM-1021, an antibody-drug conjugate designed to deliver a cancer-killing drug directly to tumor cells. It enrolls 117 adults with advanced solid tumors or B-cell lymphomas that have not responded to standard treatments. The main goals are to check saf…
Phase: PHASE1 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for advanced cancer: experimental drug targets Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…
Phase: EARLY_PHASE1 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New Antibody-Drug conjugate IM-1617 enters human trials for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called IM-1617 in people with advanced solid tumors (cancers that have spread or can't be removed by surgery). The study has two parts: first, finding a safe dose, then testing that dose in more people to see how well it works and how …
Phase: PHASE1 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Healthy volunteers help compare two pill forms of varegacestat
Knowledge-focused Recruiting nowThis early-stage trial enrolls 20 healthy adults to compare how two different capsule forms of the drug varegacestat are absorbed by the body. Participants will receive both forms in a random order under fasting conditions. The study measures drug levels in the blood and checks f…
Phase: PHASE1 • Sponsor: Immunome, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC